Brimonidine Purite 0.15% versus Dorzolamide 2% Each Given Twice Daily to Reduce the Intraocular Pressure in Patients with Open-angle Glaucoma or Ocular Hypertension

Abstract

Abstract: : Purpose: To evaluate the efficacy and safety of brimonidine purite versus dorzolamide given twice daily as monotherapy in primary open-angle glaucoma or ocular hypertensive patients. Methods: This was a double-masked, multicenter, prospective, randomized, crossover comparison. Qualified patients were washed out from their previous medication and randomized to brimonidine purite 0.15% or dorzolamide 2% for the first four-week treatment period. Patients again were washed out for four weeks and begun on the opposite medication for the second four-week period. Pressures were measured at 08:00 (trough) and +2, +10 and +12 hours after dosing at each baseline and at the end of each treatment period. Results: Thirty-three patients entered and completed this trial. The baseline diurnal intraocular pressure (IOP) for patients on brimonidine purite was 22.9 ± 2.8 and 22.2 ± 2.4 mm Hg for dorzolamide. This study found that the 08:00 trough IOP following four weeks of therapy was 21.0 ± 3.7 for brimonidine purite and 21.0 ± 3.1 mm Hg for dorzolamide (P = 0.90). The mean diurnal pressure was 19.3 ± 3.1 for brimonidine purite and 19.8 ± 2.4 mm Hg for dorzolamide (P = 0.46). Dorzolamide caused more ocular stinging upon instillation (n = 8) than brimonidine purite (n = 1) (P = 0.02). No statistical differences existed between groups for systemic adverse events. Conclusions: This study suggests similar efficacy and safety between monotherapy treatment with brimonidine purite and dorzolamide each given twice daily in primary open-angle glaucoma or ocular hypertensive patients.

Keywords: intraocular pressure • drug toxicity/drug effects • clinical (human) or epidemiologic studies: tre